<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Neuronal injury in <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> is partly mediated by cytotoxic reactive oxygen species </plain></SENT>
<SENT sid="1" pm="."><plain>Although the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> <z:chebi fb="6" ids="22652,29073">ascorbic acid</z:chebi> (AA) or <z:chebi fb="122" ids="21241">vitamin C</z:chebi> does not penetrate the blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>), its oxidized form, <z:chebi fb="0" ids="17242,27956">dehydroascorbic acid</z:chebi> (DHA), enters the brain by means of facilitative transport </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that i.v </plain></SENT>
<SENT sid="3" pm="."><plain>DHA would improve outcome after <z:hpo ids='HP_0001297'>stroke</z:hpo> because of its ability to cross the <z:chebi fb="2" ids="33602">BBB</z:chebi> and augment brain <z:chebi fb="11" ids="22586">antioxidant</z:chebi> levels </plain></SENT>
<SENT sid="4" pm="."><plain>Reversible or permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was created by intraluminal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in mice treated with vehicle, AA, or DHA (40, 250, or 500 mg/kg), either before or after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Given before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, DHA caused dose-dependent increases in postreperfusion cerebral blood flow, with reductions in neurological deficit and mortality </plain></SENT>
<SENT sid="6" pm="."><plain>In reperfused <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, mean <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was reduced from 53% and 59% in vehicle- and AA-treated animals, respectively, to 15% in 250 mg/kg DHA-treated animals (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Similar significant reductions occurred in nonreperfused <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Delayed postischemic DHA administration after 15 min or 3 h also mediated improved outcomes </plain></SENT>
<SENT sid="9" pm="."><plain>DHA (250 mg/kg or 500 mg/kg) administered at 3 h postischemia reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume by 6- to 9-fold, to only 5% with the highest DHA dose (P &lt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, AA had no effect on <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes, mortality, or neurological deficits </plain></SENT>
<SENT sid="11" pm="."><plain>No differences in the incidence of <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> occurred </plain></SENT>
<SENT sid="12" pm="."><plain>Unlike exogenous AA, DHA confers in vivo, dose-dependent neuroprotection in reperfused and nonreperfused <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> at clinically relevant times </plain></SENT>
<SENT sid="13" pm="."><plain>As a naturally occurring interconvertible form of AA with <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability, DHA represents a promising pharmacological therapy for <z:hpo ids='HP_0001297'>stroke</z:hpo> based on its effects in this model of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>